Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Medicine, University of California at Irvine 1997 - 1999
  • Fellow, Hematology, Oncology, University of Chicago 1993 - 1997
  • Resident, National University Hospital (Singapore) 1991 - 1993
  • M.B.B.Ch., University of Cambridge (UK) 1987
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Than, H, Lye, WK, Sng, C, Allen, JC, Ong, ST, and Chuah, C. "BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients." Leukemia & Lymphoma 60, no. 1 (January 2019): 234-237.  Full Text
    • Leidy-Davis, T, Cheng, K, Goodwin, LO, Morgan, JL, Juan, WC, Roca, X, Ong, ST, and Bergstrom, DE. "Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches." Scientific Reports 8, no. 1 (October 9, 2018): 15028-null.  Full Text
    • Ng, KP, Manjeri, A, Lee, LM, Chan, ZE, Tan, CY, Tan, QD, Majeed, A, Lee, KL, Chuah, C, Suda, T, and Ong, ST. "The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target." Plos One 13, no. 10 (January 2018): e0205254-null.  Full Text
    • Liu, J, Bhadra, M, Sinnakannu, JR, Yue, WL, Tan, CW, Rigo, F, Ong, ST, and Roca, X. "Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides." Oncotarget 8, no. 44 (September 6, 2017): 77567-77585.  Full Text
    • Soh, SX, Siddiqui, FJ, Allen, JC, Kim, GW, Lee, JC, Yatabe, Y, Soda, M, Mano, H, Soo, RA, Chin, T-M, Ebi, H, Yano, S, Matsuo, K, Niu, X, Lu, S, Isobe, K, Lee, J-H, Yang, JC, Zhao, M, Zhou, C, Lee, J-K, Lee, S-H, Lee, JY, Ahn, M-J, Tan, TJ, Tan, DS, Tan, E-H, Ong, ST, and Lim, W-T. "A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer." Oncotarget 8, no. 25 (June 2017): 41474-41486. (Review)  Full Text
    • Tanimoto, A, Takeuchi, S, Arai, S, Fukuda, K, Yamada, T, Roca, X, Ong, ST, and Yano, S. "Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 12 (June 2017): 3139-3149.  Full Text
    • Cherian, J, Nacro, K, Poh, ZY, Guo, S, Jeyaraj, DA, Wong, YX, Ho, M, Yang, HY, Joy, JK, Kwek, ZP, Liu, B, Wee, JLK, Ong, EHQ, Choong, ML, Poulsen, A, Lee, MA, Pendharkar, V, Ding, LJ, Manoharan, V, Chew, YS, Sangthongpitag, K, Lim, S, Ong, ST, Hill, J, and Keller, TH. "Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells." Journal of Medicinal Chemistry 59, no. 7 (April 5, 2016): 3063-3078.  Full Text
    • Ko, TK, Chin, HS, Chuah, CTH, Huang, JWJ, Ng, K-P, Khaw, SL, Huang, DCS, and Ong, ST. "The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia." Oncotarget 7, no. 3 (January 2016): 2721-2733.  Full Text
    • Yano, S, Tanimoto, A, Arai, S, Fukuda, K, Ong, ST, and Takeuchi, S. "HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer." JOURNAL OF THORACIC ONCOLOGY 10, no. 9 (September 2015): S296-S297.  Link to Item
    • Tsai, BP, Jimenez, J, Lim, S, Fitzgerald, KD, Zhang, M, Chuah, CTH, Axelrod, H, Wilson, L, Ong, ST, Semler, BL, and Waterman, ML. "A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1." Open biology 4, no. 11 (November 2014): 140180-.  Full Text
    • Ko, TK, Chuah, CTH, Huang, JWJ, Ng, K-P, and Ong, ST. "The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors." Oncotarget 5, no. 19 (October 2014): 9033-9038.  Full Text
    • Ong, ST, Chuah, CTH, Ko, TK, Hillmer, AM, and Lim, W-T. "Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia." Nature Medicine 20, no. 10 (October 2014): 1090-1091. (Letter)  Full Text
    • Ong, ST. "Heritable resistance to tyrosine kinase inhibitors." Clinical advances in hematology & oncology : H&O 12, no. 7 (July 2014): 454-457.
    • Ng, KP, Manjeri, A, Lee, KL, Huang, W, Tan, SY, Chuah, CTH, Poellinger, L, and Ong, ST. "Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition." BLOOD 123, no. 21 (May 22, 2014): 3316-3326.  Full Text  Link to Item
    • Juan, WC, Roca, X, and Ong, ST. "Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing." PLoS ONE 9, no. 4 (January 2014): e95210-.  Full Text
    • Soh, SX, Lim, JYS, Huang, JWJ, Jiang, N, Yeoh, AEJ, and Ong, ST. "Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia." PloS one 9, no. 8 (January 2014): e103435-.  Full Text
    • Soh, S, and Ong, ST. "A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies." Rinsho Ketsueki 54, no. 10 (October 2013): 1714-1719. (Review)  Link to Item
    • Lim, S, Saw, TY, Zhang, M, Janes, MR, Nacro, K, Hill, J, Lim, AQ, Chang, C-T, Fruman, DA, Rizzieri, DA, Tan, SY, Fan, H, Chuah, CTH, and Ong, ST. "Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function." Proceedings of the National Academy of Sciences of the United States of America 110, no. 25 (June 4, 2013): E2298-E2307.  Full Text
    • Juan, WC, Ko, TK, Roca, X, and Ong, ST. "Abstract 4958: Identification of cis-regulatory elements in a BIM deletion polymorphism that regulate splicing and generation of non-apoptotic BIM isoforms." Cancer Research 72, no. 8 Supplement (April 15, 2012): 4958-4958.  Full Text
    • Ng, KP, Hillmer, AM, Chuah, CTH, Juan, WC, Ko, TK, Teo, ASM, Ariyaratne, PN, Takahashi, N, Sawada, K, Fei, Y, Soh, S, Lee, WH, Huang, JWJ, Allen, JC, Woo, XY, Nagarajan, N, Kumar, V, Thalamuthu, A, Poh, WT, Ang, AL, Mya, HT, How, GF, Yang, LY, Koh, LP, Chowbay, B, Chang, C-T, Nadarajan, VS, Chng, WJ, Than, H, Lim, LC, Goh, YT, Zhang, S, Poh, D, Tan, P, Seet, J-E, Ang, M-K, Chau, N-M, Ng, Q-S, Tan, DSW, Soda, M, Isobe, K, Nöthen, MM, Wong, TY, Shahab, A, Ruan, X, Cacheux-Rataboul, V, Sung, W-K, Tan, EH, Yatabe, Y, Mano, H, Soo, RA, Chin, TM, Lim, W-T, Ruan, Y, and Ong, ST. "A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer." Nature Medicine 18, no. 4 (March 18, 2012): 521-528.  Full Text
    • Juan, WC, and Ong, ST. "The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia." Prog Mol Biol Transl Sci 106 (2012): 107-142. (Review)  Full Text  Link to Item
    • Janes, MR, Limon, JJ, So, L, Chen, J, Lim, RJ, Chavez, MA, Vu, C, Lilly, MB, Mallya, S, Ong, ST, Konopleva, M, Martin, MB, Ren, P, Liu, Y, Rommel, C, and Fruman, DA. "Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor." Nature Medicine 16, no. 2 (February 2010): 205-213.  Full Text
    • Zhang, M, Fu, W, Prabhu, S, Moore, JC, Ko, J, Kim, JW, Druker, BJ, Trapp, V, Fruehauf, J, Gram, H, Fan, HY, and Ong, ST. "Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance." Molecular and Cellular Biology 28, no. 20 (October 2008): 6496-6509.  Full Text
    • Prabhu, S, Saadat, D, Zhang, M, Halbur, L, Fruehauf, JP, and Ong, ST. "A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation." Oncogene 26, no. 8 (February 2007): 1188-1200.  Full Text
    • Arechiga, AF, Bell, BD, Leverrier, S, Weist, BM, Porter, M, Wu, Z, Kanno, Y, Ramos, SJ, Ong, ST, Siegel, R, and Walsh, CM. "A Fas-associated death domain protein/caspase-8-signaling axis promotes S-phase entry and maintains S6 kinase activity in T cells responding to IL-2 1." Journal of Immunology 179, no. 8 (2007): 5291-5300.
    • Moore, JC, Dennehey, CF, Anavim, A, Kong, KM, and Ong, ST. "Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia." European Journal of Haematology 76, no. 5 (2006): 444-446.  Full Text
    • Ly, C, Arechiga, AF, Melo, JV, Walsh, CM, and Ong, ST. "Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin." Cancer Research 63, no. 18 (2003): 5716-5722.
    • Ong, ST, Ly, C, Nguyen, M, Brightman, BK, and Fan, H. "Expression profiling of a transformed thymocyte cell line undergoing maturation in vitro identifies multiple genes involved in positive selection." Cellular Immunology 221, no. 1 (2003): 64-79.  Full Text
    • Peters, UR, Hasse, U, Oppliger, E, Tschan, M, Ong, ST, Rassool, FV, Borisch, B, Tobler, A, and Fey, MF. "Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia." Oncogene 18, no. 1 (1999): 79-85.  Full Text
    • Ong, ST, Hackbarth, ML, Degenstein, LC, Baunoch, DA, Anastasi, J, and McKeithan, TW. "Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice." Oncogene 16, no. 18 (1998): 2333-2343.
    • Ong, ST, and Beau, MML. "Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma." Seminars in Oncology 25, no. 4 (1998): 447-460.
    • Ong, ST, Fong, KM, Bader, SA, Minna, JD, Le Beau, MM, McKeithan, TW, and Rassool, FV. "Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines." Genes, chromosomes & cancer 20, no. 1 (September 1997): 16-23.  Full Text
    • Ong, ST, Fong, KM, Bader, SA, Minna, JD, Le Beau, MM, McKeithan, TW, and Rassool, FV. "Precise localization of theFHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affectFHIT transcription in tumor cell lines." Genes, Chromosomes and Cancer 20, no. 1 (September 1997): 16-23.  Full Text
    • Fong, KM, Biesterveld, EJ, Virmani, A, Wistuba, I, Sekido, Y, Bader, SA, Ahmadian, M, Ong, ST, Rassool, FV, Zimmerman, PV, Giaccone, G, Gazdar, AF, and Minna, JD. "FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations." Cancer Research 57, no. 11 (1997): 2256-2267.
    • Ong, ST, Stupp, R, and Ultmann, JE. "The sixth Lugano conference: Basic science papers." Annals of Oncology 8, no. SUPPL. 2 (January 1, 1997).  Full Text
    • Ultmann, JE, Ong, ST, and Stupp, R. "One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress?." Annals of Oncology : Official Journal of the European Society for Medical Oncology 8 Suppl 1 (January 1997): 1-3. (Review)  Full Text
    • Ong, ST, and Vogelzang, NJ. "Chemotherapy in malignant pleural mesothelioma. A review." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 14, no. 3 (March 1996): 1007-1017. (Review)  Full Text
    • Ong, ST, Koeppen, H, Larson, RA, and Olopade, OI. "Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine [1]." Blood 88, no. 6 (1996): 2354-2355.
    • Rassool, FV, Beau, MML, Shen, M-L, Neilly, ME, III, RE, Ong, ST, Boldog, F, Drabkin, H, McCarroll, R, and McKeithan, TW. "Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2." Genomics 35, no. 1 (1996): 109-117.  Full Text
    • Ong, ST, and Larson, RA. "Current management of acute lymphoblastic leukemia in adults." ONCOLOGY 9, no. 5 (1995): 433-442.
    • Ultmann, JE, and Ong, ST. "The cost-benefit ratio of the cure of Hodgkin's disease." The cancer journal from Scientific American. 1, no. 1 (1995): 23-25.
    • Ong, ST, and Kueh, YK. "Hepatic candidiasis: Persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia." Annals of the Academy of Medicine Singapore 22, no. 2 (1993): 257-260.

  • Book Sections

    • Than, H, Chuah, C, and Ong, ST. "Molecular mechanism of TKI resistance and potential approaches to overcome resistance." In Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia, 167-182. January 1, 2015.  Full Text

  • Conference Papers

    • Ko, TK, Soh, XXS, Yu, W, Winter, PS, Pathiraja, T, Javed, A, Malik, S, Tan, JHJ, Chuah, C, Takahashi, N, Bhatia, R, Chng, WJ, Valent, P, Cerny-Reiterer, S, Ng, KP, Tennakoon, C, Hoi, Q, Guan, P, Teo, ASM, Lee, WH, Tan, P, Sung, WK, Ng, P, Hillmer, A, Wood, KC, Rozen, S, and Ong, ST. "Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches." December 3, 2015.  Link to Item
    • Ong, ST, Pathiraja, T, Javed, A, Soh, XXS, Malik, S, Tan, JNJ, Ko, TK, Chuah, C, Takahashi, N, Bhatia, R, Ng, KP, Chng, WJ, Tennakoon, C, Hoi, Q, Guan, P, Teo, ASM, Lee, WH, Tan, P, Sung, WK, Ng, P, and Hillmer, A. "The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia." December 3, 2015.  Link to Item
    • Ng, KP, Manjeri, A, Lee, KL, Huang, W, Tan, SY, Chuah, CTH, Poellinger, L, and Ong, ST. "Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition." May 2014.  Full Text
    • Lim, S, Saw, TY, Zhang, M, Janes, MR, Nacro, K, Hill, J, Lim, AQ, Chang, C-T, Fruman, DA, Rizzieri, DA, Tan, SY, Fan, H, Chuah, CTH, and Ong, ST. "Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function." United States. June 18, 2013.  Full Text  Link to Item
    • Hillmer, AM, Ng, K-P, Chuah, C, Juan, WC, Ko, T-K, Teo, ASM, Ariyaratne, PN, Takahashi, N, Sawada, K, Fei, Y, Lee, WH, Huang, W, Jr, AJC, Woo, XT, Nagarajan, N, Kumar, V, Thalamuthu, A, Poh, WT, Ang, AL, Mya, HT, How, GF, Yang, LY, Koh, LP, Nadarajan, VS, Chng, W-J, Than, H, Lim, LC, Goh, Y-T, Noethen, MM, Wong, TY, Shahab, A, Ruan, X, Cacheux-Rataboul, V, Sung, W-K, Ruan, Y, and Ong, ST. "A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia." November 18, 2011.  Link to Item
    • Lim, S, Saw, TY, Chuah, C, and Ong, ST. "Overexpression and Phosphorylation of eIF4E Is Required for Beta-Catenin Activation in Blast Crisis Chronic Myelogenous Leukemia." November 20, 2009.  Link to Item
    • Ng, K-P, Poh, TY, Sun, WT, Chuah, C, and Ong, ST. "Physiologic Hypoxia Protects Chronic Myelogenous Leukemia Progenitors From Elimination by Imatinib Mesylate." November 20, 2009.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.